News Focus
News Focus
icon url

X Master

10/19/22 1:31 AM

#523056 RE: HyGro #523055

HyGro you sure defend the electric helmet. Why? It has a poor survival rate and it diminishes the overall quality of life.
icon url

hoffmann6383

10/19/22 7:57 AM

#523070 RE: HyGro #523055

Agreed, optune has all sorts of data issues. on the other hand, can't really manipulate the beating hearts that nwbo showed.

I started reading the repeated bullshit narrative in the last paragraph but then stopped after half a line.
icon url

scotty3371

10/19/22 8:09 AM

#523073 RE: HyGro #523055

Call novacure and ask for how many 5 year survivors they have. Ask them how many do they know of?

They will not answer.
icon url

dstock07734

10/19/22 12:50 PM

#523174 RE: HyGro #523055

The reason NWBO adopted new primary ending point is because of pseudoprogression. That's why the trial took so long becuase they had to use OS as primary ending point. Did I get that right?

Is Data manipulation in clinical trials a crime? It is very serious accusation. If you are so sure about it, file Citizen Petition to FDA for the good of the public.

https://www.fda.gov/regulatory-information/dockets-management/instructions-submitting-citizen-petitions-cps-electronically
icon url

CherryTree1

10/19/22 1:21 PM

#523188 RE: HyGro #523055

Completely false and the protocol NWBO is following have been standard practice for some time.Here is information from 2010
http://onbiostatistics.blogspot.com/2010/04/when-to-finalize-statistical-analysis.html

When to Finalize the Statistical Analysis Plan (SAP)?
"The statistical analysis plan may be written as a separate document to be completed after finalising the protocol. In this document, a more technical and detailed elaboration of the principal features stated in the protocol may be included. The plan may include detailed procedures for executing the statistical analysis of the primary and secondary variables and other data. The plan should be reviewed and possibly updated as a result of the blind review of the data (see 7.1 for definition) and should be finalised before breaking the blind. Formal records should be kept of when the statistical analysis plan was finalised as well as when the blind was subsequently broken.
If the blind review suggests changes to the principal features stated in the protocol, these should be documented in a protocol amendment. Otherwise, it will suffice to update the statistical analysis plan with the considerations suggested from the blind review. Only results from analyses envisaged in the protocol (including amendments) can be regarded as confirmatory."

This indicated that the ICH principal is followed as long as the statistical analysis plan is finalized or signed off prior to the study unblinding (or database lock if it is open label study). I believe this is the common practice in industry.



The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines.